Stay updated with breaking news from Aha 2023. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A group of 13 leading experts provides their perspectives on the top news in cardiovascular medicine from 2023, with responses ranging from novel approvals to new semaglutide data to gene therapy and more.
ORBITA-2 trial: Percutaneous coronary intervention improved chest pain and quality of life vs. placebo in stable angina patients.
In the phase 2 ReVeRA trial, etripamil nasal spray provided a marked reduction in ventricular rates among patients with atrial fibrillation and rapid ventricular rates.
The MINT trial, which included 3504 patients with acute MI and anemia, shows a trend favoring liberal transfusion, indicating a potential for improved outcomes.
Marc Bonaca, MD, discusses an AHA 2023 study he led examining trends in discordance between LVEF and ICD-10 codes used in heart failure hospitalizations.